Ernexa outlines progress toward clinical testing of ERNA-101 for ovarian cancer, highlighting its approach to turn immunologically 'cold' tumors into recognizable targets. Preclinical data show complete tumor clearance and 100% long-term survival when ERNA-101 is paired with PD-1 blockade, supporting an IND in Q3 2026 and a Q4 2026 start for a Phase 1 trial. The off-the-shelf iMSC platform could boost manufacturing scalability.
Ernexa Therapeutics Inc has seen a significant share price increase following an investor segment featuring Chief Scientific Officer Dr. Robert Pierce. The company is gaining attention due to the potential of its drug ERNA-101 for treating ovarian cancer, indicating potential growth and interest from investors.
